Arax Advisory Partners’s UroGen Pharma URGN Stock Holding History

Arax Advisory Partners’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-14	Closed	-$328	–	4346
2025 Q4	$328	Sell	14 -12,365	-100%	-$268K	﹤0.01%	3661
2025 Q3	$247K	Buy	+12,379	New	+$222K	﹤0.01%	1167
2024 Q4	–	Sell	-56	Closed	-$712	–	2752
2024 Q3	$712	Hold	56	–	–	﹤0.01%	2343
2024 Q2	$940	Buy	+56	New	+$797	﹤0.01%	2188

Other funds holding URGN

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Arax Advisory Partners's URGN Position: Q1 2026 in Review

Arax Advisory Partners sold out of UroGen Pharma (URGN) in Q1 2026, closing a stake of 14 shares — an estimated $328 sold.

Arax Advisory Partners first reported a position in URGN in Q2 2024 and held it in 4 quarters. The position peaked at $247K in Q3 2025. 172 funds tracked by Wall St. Rank hold URGN as of Q1 2026.

Arax Advisory Partners reported no remaining UroGen Pharma position as of Q1 2026 after selling out during the quarter.
Arax Advisory Partners sold 14 UroGen Pharma shares in Q1 2026, an estimated $328.
Arax Advisory Partners first reported a position in UroGen Pharma in Q2 2024 and held it in 4 quarters.
Arax Advisory Partners's UroGen Pharma position peaked at $247K in Q3 2025.
172 funds tracked by Wall St. Rank held UroGen Pharma as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.